Carmelina M.
- Country
- Italy
- Department
- Nefrologia e dialisi
Research Overview
- Phase III Randomized Double‑Blind Placebo‑Controlled Trial of Elecoglipron (AZD5004) on Renal Decline and Mortality in Adults with Chronic Kidney Disease
- Evaluation of Corticosteroids, Dapagliflozin, and RASBs on Proteinuria in IgA Nephropathy Patients with Active and Chronic Renal Lesions
- A Phase 3a Randomized Controlled Trial Comparing Metformin and Tolvaptan in Adults with Autosomal Dominant Polycystic Kidney Disease
Data & Insights
Has run more than one trial at 45 of 410 partner sites.
Specializations
Nephrology
Specializes in treating IgA nephropathy (IgAN), investigating targeted therapeutic approaches based on kidney biopsy findings. Focuses on evaluating early intervention strategies and alternative treatment methods to manage proteinuria.
- Personalized treatment protocols
- Renal biopsy assessment
- Proteinuria management
Explores the effectiveness of corticosteroid therapy and RAS blockers in different patient populations.
Cardiovascular Nephrology
Investigates atherosclerotic cardiovascular disease in end-stage kidney disease patients undergoing dialysis. Studies innovative therapeutic approaches targeting inflammatory markers in dialysis patients.
- Cardiovascular outcomes in ESKD
- Dialysis management
- Inflammatory biomarkers
Evaluates novel treatments for cardiovascular complications in dialysis patients.
Genetic Kidney Disorders
Conducts research in Autosomal Dominant Polycystic Kidney Disease (ADPKD), comparing different therapeutic approaches to slow disease progression. Explores alternative treatment options to preserve kidney function.
- ADPKD management
- Kidney function preservation
- Progressive disease treatment
Evaluates comparative effectiveness of established and novel therapeutic agents in genetic kidney disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.